Literature DB >> 2476549

The nonoxime bispyridinium compound SAD-128 alters the kinetic properties of the nicotinic acetylcholine receptor ion channel: a possible mechanism for antidotal effects.

M Alkondon1, E X Albuquerque.   

Abstract

The effects of SAD-128 [1,1'-oxybis(methylene) bis 4-(1,1-dimethylethyl) pyridinium dichloride], a nonoxime bispyridinium compound, were investigated on the nicotinic acetylcholine receptor-ion channels of frog muscle fibers using end-plate current (EPC) and single channel current measurement techniques. SAD-128 decreased the EPC peak amplitude in a concentration-dependent manner and caused nonlinearity in the current-voltage plots. The time constant of EPC decay was prolonged by SAD-128 (10-200 microM) at potentials between +50 and -90 mV without loss of the single exponential decay. However, at -100 mV and below, biphasic decays of the EPCs were observed in the presence of the drug. The time constant of the fast phase of the EPC decay decreased, whereas that of the slow phase increased, with either hyperpolarization or increasing concentration of the drug. SAD-128 weakly inhibited acetylcholinesterase in frog sartorius muscle. At the single-channel current level, SAD-128 reduced the mean channel open time and produced a blocked state evidenced as an additional phase in the closed time distribution. The agent induced a biphasic burst time distribution whose fast component became faster and slow component slower with increasing concentration and hyperpolarization. The present study provides more details regarding the kinetics of the nicotinic acetylcholine receptor ion channel-blocking mechanisms and a correlation between single-channel currents and macroscopic events. The ability of SAD-128 to block the nicotinic acetylcholine receptor may underlie its efficacy in counteracting lethal effect of organophosphorus compounds.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476549

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Effects of organophosphorus anticholinesterases on nicotinic receptor ion channels at adult mouse muscle endplates.

Authors:  J E Tattersall
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

2.  Pathophysiological studies of neuromuscular function in subacute organophosphate poisoning induced by phosmet.

Authors:  J L Good; R K Khurana; R F Mayer; W M Cintra; E X Albuquerque
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-03       Impact factor: 10.154

3.  Ion channel blockade by oximes and recovery of diaphragm muscle from soman poisoning in vitro.

Authors:  J E Tattersall
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

4.  Acute toxicity of several organophosphorous insecticides and protection by cholinergic antagonists and 2-PAM on Artemia salina larvae.

Authors:  S Sánchez-Fortún; F Sanz; M V Barahona
Journal:  Arch Environ Contam Toxicol       Date:  1996-10       Impact factor: 2.804

Review 5.  Nicotinic antagonists in the treatment of nerve agent intoxication.

Authors:  Robert D Sheridan; Andrew P Smith; Simon R Turner; John E H Tattersall
Journal:  J R Soc Med       Date:  2005-03       Impact factor: 18.000

6.  Bispyridinium Compounds Inhibit Both Muscle and Neuronal Nicotinic Acetylcholine Receptors in Human Cell Lines.

Authors:  Avi Ring; Bjorn Oddvar Strom; Simon R Turner; Christopher M Timperley; Michael Bird; A Christopher Green; John E Chad; Franz Worek; John E H Tattersall
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

7.  Development of small bisquaternary cholinesterase inhibitors as drugs for pre-treatment of nerve agent poisonings.

Authors:  Kamil Kuca; Jana Zdarova Karasova; Ondrej Soukup; Jiri Kassa; Eva Novotna; Vendula Sepsova; Anna Horova; Jaroslav Pejchal; Martina Hrabinova; Eva Vodakova; Daniel Jun; Eugenie Nepovimova; Martin Valis; Kamil Musilek
Journal:  Drug Des Devel Ther       Date:  2018-03-09       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.